Skip to main content

Table 1 Baseline characteristics of the population enrolled in the study

From: The ratio of Th17/Treg cells as a risk indicator in early acute respiratory distress syndrome

Variables Control Acute respiratory distress syndrome P -value
Total Mild Moderate Severe
Number 26 79 24 28 27  
Age, years 54.00 ± 13.77 55.03 ± 14.42 55.17 ± 15.45 53.36 ± 13.34 57.63 ± 15.57 0.714
Gender, male/female, n 14/12 44/35 13/11 15/13 16/11 0.971
BMI, kg/m2 22.44 ± 3.53 24.03 ± 4.13 24.72 ± 4.98 24.67 ± 3.84 24.26 ± 3.93 0.150
Cause of ARDS       
Pneumonia   25 6 9 10  
Non-pulmonary sepsis   19 4 8 7  
Trauma   23 9 6 8  
Aspiration   5 2 2 1  
Multiple transfusions   4 2 2   
Others   3 1 1 1  
APACHE II score   22 (20 to 26) 20 (18 to 22) 23 (21 to 26)* 25 (22 to 27)* <0.001
SOFA score   11.0 (10.0 to 13.0) 9.5 (7.0 to 11.8) 11.0 (10.0 to 13.0)* 12.0 (11.0 to 13.0)* <0.001
Lung injury score   2.3 (2.1 to 2.8) 2.0 (1.9 to 2.1) 2.3 (2.1 to 2.5)* 2.9 (2.7 to 3.2)*# <0.001
PaO2/FiO2 (mmHg)   138 (76 to 222) 258 (223 to 273) 139 (120 to 158)* 67 (59 to 79)*# <0.001
CRP, mg/L 4.97 (3.83 to 6.12) 135.84 (116.83 to 156.79) 116.69 (104.17 to 133.33) 130.97 (123.40 to 154.45) 156.85 (143.59 to 185.36)* <0.001
PCT, ng/mL 0.04 (0.02 to 0.06) 1.56 (1.24 to 1.83) 1.24 (1.05 to 136) 1.47 (1.27 to 1.66) 2.04 (1.62 to 2.61)*# <0.001
Leukocytes, 109/L 6.8 (5.6 to 8.2) 12.9 (11.2 to 14.8) 11.8 (10.5 to 12.8) 12.4 (10.7 to 13.7) 15.3 (13.6 to 17.6)*# <0.001
Monocytes, 109/L 0.58 (0.46 to 0.69) 1.05 (0.92 to 1.23) 0.95 (0.84 to 1.13) 1.04 (0.88 to 1.23) 1.12 (1.04 to 1.1.26)* <0.001
Lymphocytes, 109/L 3.09 (2.80 to 3.52) 5.35 (4.25 to 6.47) 4.24 (3.93 to 4.96) 5.24 (4.19 to 6.06)* 6.72 (5.69 to 7.45)*# <0.001
Th17 cells, % of CD4+ 0.71 (0.59 to 0.94) 4.27 (3.67 to 6.02) 3.54 (3.17 to 3.94) 4.16 (3.96 to 4.54)* 6.42 (5.96 to 6.91)*# <0.001
Treg cells, % of CD4+ 3.11 (2.70 to 3.44) 5.37 (4.98 to 6.07) 4.82 (4.50 to 5.18) 5.46 (5.25 to 5.81)* 6.18 (5.82 to 6.57)*# <0.001
Th17/Treg ratio 0.25 ± 0.09 0.86 ± 0.20 0.74 ± 0.12 0.77 ± 0.10 1.01 ± 0.18*# <0.001
IL-6, pg/mL 11.70 ± 1.31 758.33 ± 70.03 721.53 ± 54.43 763.62 ± 76.96* 785.56 ± 62.36* <0.001
IL-17, pg/mL 20.27 ± 4.12 199.59 ± 68.12 139.42 ± 25.51 204.75 ± 37.64* 247.72 ± 78.08*# <0.001
IL-10, pg/mL 123.04 ± 20.53 131.19 ± 19.94 137.8 ± 19.17 132.49 ± 20.14 124.17 ± 18.87 0.029
TGF-β1, pg/mL 193.48 ± 46.48 209.92 ± 51.00 219.30 ± 61.84 200.30 ± 41.77 211.55 ± 49.25 0.264
28-day mortality, n, %   32 (40.5%) 7 (29.17%) 12 (42.86%) 13 (48.15%)  
  1. Quantitative data with a normal distribution are presented as mean ± SD. Quantitative data with a non-normal distribution are presented as median (IQR). Qualitative data are presented as number (%). P-value for the four groups (mild, moderate, severe ARDS, and control groups); *P <0.01 versus mild ARDS; # P <0.01 versus moderate ARDS. BMI, body mass index; APACHE, acute physiologic and chronic health evaluation; SOFA, sequential organ failure assessment; CRP, C-reactive protein; PCT, procalcitonin.